# 42 U.S.C. 1395w-3a Use of average sales price payment methodology

42 U.S.C. 1395w-3a Use of average sales price payment methodology, “Use of average sales price payment methodology”, is a U.S. Code section of [Part B—Supplementary Medical Insurance Benefits for Aged and Disabled](https://ontology.bommaritollc.com/id/01a0f07c-d37b-74c2-a896-e21583f71c3d); in force.

IRI: <https://ontology.bommaritollc.com/id/01a0f07c-e101-77ca-9302-626ce27357ac>

Within: [Title 42—The Public Health and Welfare](https://ontology.bommaritollc.com/id/01a0f07c-d251-723d-b1d9-a44e9ccd25c7) › [Chapter 7—Social Security](https://ontology.bommaritollc.com/id/01a0f07c-d363-76d2-9057-fafa67260f8f) › [Subchapter XVIII—Health Insurance for Aged and Disabled](https://ontology.bommaritollc.com/id/01a0f07c-d37a-75dc-8b16-857e761e15ce) › [Part B—Supplementary Medical Insurance Benefits for Aged and Disabled](https://ontology.bommaritollc.com/id/01a0f07c-d37b-74c2-a896-e21583f71c3d)

Type: [schema:Legislation](https://schema.org/Legislation)

- `adms:identifier`: [usc-section 42 U.S.C. 1395w-3a](https://ontology.bommaritollc.com/id/01a0f07c-e102-70ca-a72a-2072d1fe34f9)
- `eli:cites`:
  - [21 U.S.C. 356e Drug shortage list](https://ontology.bommaritollc.com/id/01a0f06c-ccee-7344-b4b7-63434c7ace97)
  - [42 U.S.C. 247d Public health emergencies](https://ontology.bommaritollc.com/id/01a0f07c-d961-7148-9e7e-f0bbd971a175)
  - [42 U.S.C. 256b Limitation on prices of drugs purchased by covered entities](https://ontology.bommaritollc.com/id/01a0f07c-d9be-725f-881b-75132e9a9101)
  - [42 U.S.C. 262 Regulation of biological products](https://ontology.bommaritollc.com/id/01a0f07c-d9ca-7203-a1d8-2d79c0329140)
  - [42 U.S.C. 1320a-7a Civil monetary penalties](https://ontology.bommaritollc.com/id/01a0f07c-e034-763e-8cec-fa9882a36076)
  - [42 U.S.C. 1320a-7b Criminal penalties for acts involving Federal health care programs](https://ontology.bommaritollc.com/id/01a0f07c-e035-71c1-9bc9-5835d498ccb9)
  - [42 U.S.C. 1320f Establishment of program](https://ontology.bommaritollc.com/id/01a0f07c-e07b-7379-87a5-77617d9e2ec8)
  - [42 U.S.C. 1320f-1 Selection of negotiation-eligible drugs as selected drugs](https://ontology.bommaritollc.com/id/01a0f07c-e07c-7216-b5a8-3e53bef1458d)
  - [42 U.S.C. 1395l Payment of benefits](https://ontology.bommaritollc.com/id/01a0f07c-e0c2-7095-ad6d-d895e786c4df)
  - [42 U.S.C. 1395t Federal Supplementary Medical Insurance Trust Fund](https://ontology.bommaritollc.com/id/01a0f07c-e0ca-7238-b1f6-ca4d4622633f)
  - [42 U.S.C. 1395u Provisions relating to the administration of part B](https://ontology.bommaritollc.com/id/01a0f07c-e0cc-7633-95c1-0dfd176d452e)
  - [42 U.S.C. 1395w-3a Use of average sales price payment methodology](https://ontology.bommaritollc.com/id/01a0f07c-e101-77ca-9302-626ce27357ac)
  - [42 U.S.C. 1395w-3b Competitive acquisition of outpatient drugs and biologicals](https://ontology.bommaritollc.com/id/01a0f07c-e102-70ca-a72a-207419ca07f9)
  - [42 U.S.C. 1395w-114b Manufacturer rebate for certain drugs with prices increasing faster than inflation](https://ontology.bommaritollc.com/id/01a0f07c-e122-7770-a968-a78478520c77)
  - [42 U.S.C. 1395x Definitions](https://ontology.bommaritollc.com/id/01a0f07c-e12f-7745-97f8-f2587b517dd7)
  - [42 U.S.C. 1395ff Determinations; appeals](https://ontology.bommaritollc.com/id/01a0f07c-e13d-74f7-a155-0d2f739e7163)
  - [42 U.S.C. 1395oo Provider Reimbursement Review Board](https://ontology.bommaritollc.com/id/01a0f07c-e146-737e-a8d6-7bfbc460b053)
  - [42 U.S.C. 1395rr End stage renal disease program](https://ontology.bommaritollc.com/id/01a0f07c-e149-710d-af34-7761a592b15c)
  - [42 U.S.C. 1396r-8 Payment for covered outpatient drugs](https://ontology.bommaritollc.com/id/01a0f07c-e17e-7431-ad8e-b86bb6c0b818)
- `prov:wasDerivedFrom`:
  - [evidence from https://www.govinfo.gov/app/details/USCODE-2024-title42/USCODE-2024-title42-chap7-subchapXVIII-partB-sec1395w-3a](https://ontology.bommaritollc.com/id/01a0f07c-e101-77ca-9302-626bbc6821fd)
  - [evidence from https://www.govinfo.gov/app/details/](https://ontology.bommaritollc.com/id/01a0f07d-0624-72ba-96a4-c8384b614be1)
  - [evidence from https://www.govinfo.gov/app/details/](https://ontology.bommaritollc.com/id/01a0f0d2-536f-700e-9a98-70a330252218)
  - [evidence from https://www.govinfo.gov/link/uscode/42/1395w-3a?type=usc&year=mostrecent&link-type=details](https://ontology.bommaritollc.com/id/01a10f16-17f7-7205-8653-dd64e1816d1b)
- `schema:isPartOf`: [Part B—Supplementary Medical Insurance Benefits for Aged and Disabled](https://ontology.bommaritollc.com/id/01a0f07c-d37b-74c2-a896-e21583f71c3d)
- `schema:legislationIdentifier`: 42 U.S.C. 1395w-3a
- `schema:legislationJurisdiction`: [United States](https://ontology.bommaritollc.com/id/01a0ed8e-f797-7004-b7f5-bec2695977c0)
- `schema:legislationLegalForce`: [schema:InForce](https://schema.org/InForce)
- `schema:legislationType`: [U.S. Code section](https://ontology.bommaritollc.com/vocab/leg/uscSection)
- `schema:name`: Use of average sales price payment methodology
- `schema:url`: [https://www.govinfo.gov/link/uscode/42/1395w-3a?type=usc&year=mostrecent&link-type=details](https://www.govinfo.gov/link/uscode/42/1395w-3a?type=usc&year=mostrecent&link-type=details)
- `skos:prefLabel`: 42 U.S.C. 1395w-3a Use of average sales price payment methodology

## Elsewhere

- [Official page](https://www.govinfo.gov/link/uscode/42/1395w-3a?type=usc&year=mostrecent&link-type=details) (www.govinfo.gov)
- [Source](https://www.govinfo.gov/app/details/USCODE-2024-title42/USCODE-2024-title42-chap7-subchapXVIII-partB-sec1395w-3a) (www.govinfo.gov)
- [Source](https://www.govinfo.gov/app/details/) (www.govinfo.gov)

## Pointing here

- Cited by (12; `eli:cites`):
  - [21 U.S.C. 355-2 Actions for delays of generic drugs and biosimilar biological products](https://ontology.bommaritollc.com/id/01a0f06c-ccd8-745e-84b4-4a4530dbb4da)
  - [42 U.S.C. 1320f Establishment of program](https://ontology.bommaritollc.com/id/01a0f07c-e07b-7379-87a5-77617d9e2ec8)
  - [42 U.S.C. 1320f-1 Selection of negotiation-eligible drugs as selected drugs](https://ontology.bommaritollc.com/id/01a0f07c-e07c-7216-b5a8-3e53bef1458d)
  - [42 U.S.C. 1320f-3 Negotiation and renegotiation process](https://ontology.bommaritollc.com/id/01a0f07c-e07e-750e-8424-d81ef2c9ff35)
  - [42 U.S.C. 1395l Payment of benefits](https://ontology.bommaritollc.com/id/01a0f07c-e0c2-7095-ad6d-d895e786c4df)
  - [42 U.S.C. 1395m-1 Improving policies for clinical diagnostic laboratory tests](https://ontology.bommaritollc.com/id/01a0f07c-e0c4-76fb-9ea3-1b3856d6acb3)
  - [42 U.S.C. 1395rr End stage renal disease program](https://ontology.bommaritollc.com/id/01a0f07c-e149-710d-af34-7761a592b15c)
  - [42 U.S.C. 1395u Provisions relating to the administration of part B](https://ontology.bommaritollc.com/id/01a0f07c-e0cc-7633-95c1-0dfd176d452e)
  - [42 U.S.C. 1395w-3b Competitive acquisition of outpatient drugs and biologicals](https://ontology.bommaritollc.com/id/01a0f07c-e102-70ca-a72a-207419ca07f9)
  - [42 U.S.C. 1395w-4 Payment for physicians' services](https://ontology.bommaritollc.com/id/01a0f07c-e102-70ca-a72a-2084e2d37579)
  - [42 U.S.C. 1395y Exclusions from coverage and medicare as secondary payer](https://ontology.bommaritollc.com/id/01a0f07c-e130-70eb-9421-f032f43c114c)
  - [42 U.S.C. 1396r-8 Payment for covered outpatient drugs](https://ontology.bommaritollc.com/id/01a0f07c-e17e-7431-ad8e-b86bb6c0b818)
- Amended by (6; `eli:amends`):
  - [Pub. L. 110-173](https://ontology.bommaritollc.com/id/01a0f07d-1005-728f-aec2-3e101e014fd9)
  - [Pub. L. 111-148](https://ontology.bommaritollc.com/id/01a0edf4-9b94-75cd-b382-c61cef7a811b)
  - [Pub. L. 116-260](https://ontology.bommaritollc.com/id/01a0edf4-a07a-73dc-a8c8-910cdf38f19a)
  - [Pub. L. 116-39](https://ontology.bommaritollc.com/id/01a0f07d-12a7-7354-b364-346e4aca3d1c)
  - [Pub. L. 117-169](https://ontology.bommaritollc.com/id/01a0edf4-a81c-717e-8db0-57c66c114e6c)
  - [Pub. L. 117-58](https://ontology.bommaritollc.com/id/01a0edf4-a082-72ce-a643-8ab63d89760a)
- Its changes, from (1; `eli:changes`):
  - [Pub. L. 108-173](https://ontology.bommaritollc.com/id/01a0edf4-a061-746d-96e2-fd07e446c0f1)
- Rules made under it (1; `eli:based_on`):
  - [42 CFR Part 427—Medicare Part B Drug Inflation Rebate Program](https://ontology.bommaritollc.com/id/01a0f0b4-2c83-7448-b624-e54286600736)

---
Also as: [Turtle](https://ontology.bommaritollc.com/id/01a0f07c-e101-77ca-9302-626ce27357ac.ttl), [JSON-LD](https://ontology.bommaritollc.com/id/01a0f07c-e101-77ca-9302-626ce27357ac.jsonld), [N-Triples](https://ontology.bommaritollc.com/id/01a0f07c-e101-77ca-9302-626ce27357ac.nt), [HTML](https://ontology.bommaritollc.com/id/01a0f07c-e101-77ca-9302-626ce27357ac)
Cite as: 42 U.S.C. 1395w-3a Use of average sales price payment methodology. bc-ontology, release 0.1.0-rc38, 2026-10-21. https://ontology.bommaritollc.com/id/01a0f07c-e101-77ca-9302-626ce27357ac
Release 0.1.0-rc38, graph hash 05350a11cf9d0c42fba51e92b877115781ab65cb92afcd6b172ff9f8f4abf0bd.
